TP53 and colorectal cancer: In both leukemia and colorectal cancer cells, irrespective of p53 status, low doses of Hinokiflavone treatment resulted in a transient and mild increase of MDM2 and MDMX, while moderate to high doses induced a dose-dependent downregulation of both MDM2 and MDMX.